Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047548 · ClinicalTrials.gov registry record · Phase 3
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06047548: Active Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06047548 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 400 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047548, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- The University of Texas Health Science Center at Houston - Bellaire
- Velocity Clinical Research, Dallas - Dallas
- Southern Endocrinology Associates - Mesquite
- Pinnacle Clinical Research - San Antonio
- Consano Clinical Research, LLC - Shavano Park
California
- Velocity Clinical Research, Westlake - Los Angeles
- Southern California Dermatology, Inc. - Santa Ana
- Encompass Clinical Research - Spring Valley
Florida
- New Horizon Research Center - Miami
- Oviedo Medical Research - Oviedo
Alabama
- Cahaba Research - Pelham - Pelham
Georgia
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Hawaii
- East-West Medical Research Institute - Honolulu
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Indiana
- Asha Clinical Research - Munster - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06047548
The ClinicalTrials.gov registry entry for NCT06047548 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06047548 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06047548 about?
NCT06047548 is a clinical study titled "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
What is the current status of trial NCT06047548?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-09-20. Estimated completion is 2026-05.
What conditions does trial NCT06047548 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06047548?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06047548?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047548 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.